文献速递骨质疏松与代谢性骨病

选择性雌激素受体调节剂联合维生素D复合制剂比单用选择性雌激素受体调节剂更能预防骨折:基于2017-2019年国家健康索赔数据库

Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
PubMed 文献 · Osteoporos Int · 2024-01-19

基于韩国国民健康保险服务数据库2017-2019年数据,比较选择性雌激素受体调节剂联合维生素D(SERM+VitD)与单用SERM在≥50岁女性中的骨折预防效果。倾向性评分匹配后每组2885例,SERM+VitD组骨质疏松性骨折风险(HR 0.77;95%CI 0.61-0.97;p=0.024)和髋部骨折风险(HR 0.25;95%CI 0.09-0.71;p=0.009)均低于SERM组,两组死亡率无差异。作者认为SERM+VitD复合制剂可考虑作为骨折风险相对较低绝经后女性的可行选择。

要点

  • SERM+VitD组骨质疏松性骨折风险低于SERM组(HR 0.77;95%CI 0.61-0.97;p=0.024)。
  • SERM+VitD组髋部骨折风险低于SERM组(HR 0.25;95%CI 0.09-0.71;p=0.009)。
  • 两组全因死亡率无差异。

核心结论

  • SERM+VitD组骨质疏松性骨折风险、尤其髋部骨折风险低于SERM组。
  • 作者认为SERM与维生素D复合制剂可考虑作为骨折风险相对较低绝经后女性的可行选择。

研究设计与样本

  • 使用韩国国民健康保险服务数据库2017-2019年数据,比较SERM+VitD与单用SERM在≥50岁女性中的骨折预防和死亡率降低效果。
  • 参与者分为SERM+VitD组与SERM组,经排除和倾向性评分匹配后每组2885例纳入分析。
  • 采用Kaplan-Meier曲线比较死亡率,Cox比例风险回归分析比较两组骨折发生和死亡风险。

主要发现

  • 骨质疏松性骨折发生率SERM+VitD组为138.6/10,000人年,SERM组为192.4/10,000人年。
  • 骨质疏松性骨折风险SERM+VitD组低于SERM组(HR 0.77;95%CI 0.61-0.97;p=0.024)。
  • 髋部骨折风险SERM+VitD组低于SERM组(HR 0.25;95%CI 0.09-0.71;p=0.009)。
  • 两组全因死亡率无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years. PURPOSE: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years. METHODS: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups. RESULTS: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. Analysis for specific fractures showed a lower hazard of hip fracture in the SERM + VitD group (HR, 0.25; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality. CONCLUSION: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Byun SE, Kim H, Lee SY, et al. Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019. Osteoporos Int. 2024. PMID: 38240755. doi:10.1007/s00198-024-07022-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。